Has Robert Weber, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,079 in general payments to Robert Weber, MD across 41 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Robert Weber, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Robert Weber, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Robert Weber, MD

Internal Medicine · Palo Alto, CANPI 1497217913

Payments from drug & device makers

$1,079in general payments, 2019–2025

Across 41 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$373
Daiichi Sankyo Inc.$206
E.r. Squibb & Sons, L.L.C.$188
Eisai Inc.$155
Genentech USA, Inc.$55
Gilead$39
plus $63 from 2 others

What the payments were for

Food & beverage$1,079100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	12	$373
Daiichi Sankyo Inc.	14	$206
E.r. Squibb & Sons, L.L.C.	3	$188
Eisai Inc.	6	$155
Genentech USA, Inc.	2	$55
Gilead(2 entities)	2	$39
Pfizer	1	$38
AbbVie	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Reblozyl$135

How this compares

$1,079 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Medicare billing

Part B allowed, 2024

$3,713

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TymlosAbaloparatide	14	$37,357
Teriparatide	11	$11,000
Hydrocortisone	22	$991

Paid to pharmacies, not to this prescriber.

Other internal medicine in Palo Alto

Andrew ChengSouth San Francisco$55.1M
Joel NeutelTustin$34.9M
Donald BrandonSan Diego$34M
William TownerLos Angeles$27.4M
Rahul AggarwalSan Francisco$24M
Masoud AzizadNorthridge$21.1M
Helen StaceyWalnut Creek$20.4M
Rohit Loombala Jolla$15.1M
Zeid KayaliColton$14.2M
Alexandra DrakakiSanta Monica$14.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →